---
layout: default
title: Valine
parent: 僅模型預測 (L5)
nav_order: 454
evidence_level: L5
indication_count: 10
---

# Valine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Valine: From Essential Amino Acid Supplementation to Sclerosing Cholangitis

## One-Sentence Summary

Valine is a branched-chain essential amino acid; no approved therapeutic indication or mechanism-of-action data is on file for this candidate. The TxGNN model predicts a possible association with **Sclerosing Cholangitis**, but this is currently supported only by **0 clinical trials** and **2 observational/genetic-association publications**, neither of which tests valine as an intervention.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not established — Valine is an essential branched-chain amino acid; no approved therapeutic indication is recorded in this evidence pack |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L4 (mechanistic/association studies only, no interventional or clinical data) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for valine is not available in this evidence pack. Based on known biology, valine is one of the branched-chain amino acids (BCAAs) involved in general protein and energy metabolism; it has no established disease-specific therapeutic indication, so there is no original-indication-to-new-indication pharmacological bridge to evaluate here.

The literature supporting the sclerosing cholangitis prediction is indirect: a Mendelian randomization study (PMID 39015781) found that certain blood metabolites show causal association signals with cholestatic liver disease risk, but it does not specifically implicate valine as a treatment target. A second, older study (PMID 15790420) examined plasma tyrosine — not valine — in relation to fatigue in primary biliary cirrhosis/primary sclerosing cholangitis patients, making its direct relevance to valine limited.

**Important caveat on the wider prediction batch:** among the remaining 9 TxGNN-predicted indications for this candidate, the majority (angle-closure glaucoma, hyperthyroidism, resistance to thyroid hormone, hyperthyroxinemia, etc.) are flagged by the evidence pack itself as likely **false positives arising from nomenclature collision** — "Val" is a standard three-letter abbreviation for valine used throughout gene-mutation nomenclature (e.g., V336M, L346V, Val109), and is also a name-fragment match with the unrelated drug valsartan. None of these represent a genuine pharmacological rationale. This substantially lowers confidence in the overall prediction set for this drug and reinforces caution specifically for the top-ranked candidate as well, since it emerged from the same low-specificity signal environment.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [39015781](https://pubmed.ncbi.nlm.nih.gov/39015781/) | 2024 | Mendelian Randomization | Frontiers in Medicine | Investigated causal relationships between blood metabolites/metabolic pathways and cholestatic liver diseases (PBC/PSC); did not specifically identify valine as a causal or therapeutic factor |
| [15790420](https://pubmed.ncbi.nlm.nih.gov/15790420/) | 2005 | Observational/Correlation | BMC Gastroenterology | Examined plasma tyrosine (not valine) concentration in relation to fatigue in PBC/PSC patients; abnormal amino acid patterns noted but no valine-specific intervention data |

## South Africa Market Information

Valine (DB00161) has no SAHPRA registrations on file and is not currently marketed in South Africa (0 licenses recorded).

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: this candidate carries a **Blocking** data gap — TFDA/PI-equivalent warning and contraindication data are not currently available, which by itself prevents progression to an initial (S1) safety assessment regardless of efficacy evidence.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (sclerosing cholangitis) is supported only by indirect metabolomic association data (L4, no clinical trials, no interventional studies), and a Blocking data gap on safety/label information prevents any safety pre-assessment. In addition, most of the other 9 TxGNN-predicted indications for this drug are attributable to "Val" nomenclature collisions rather than genuine pharmacology, which lowers overall confidence in this prediction batch.

**To proceed, the following is needed:**
- TFDA/SAHPRA-equivalent label data: warnings, contraindications, and drug interactions (currently Blocking gap, DG001)
- Confirmed mechanism of action (MOA) data for valine (currently High-severity gap, DG002)
- Interventional (not purely observational/genetic) evidence directly testing valine supplementation in cholestatic/sclerosing cholangitis populations
- Clarification of any established original indication, since none is currently on file
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

